Arcutis Biotherapeutics Inc (OQ:ARQT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 2945 Townsgate Road, Suite 110
Tel: 1-805-4185006
IR: See website
Key People
Patrick J. Heron
Independent Chairman of the Board
David Berk
Vice President - Clinical Development
Todd Franklin Watanabe
President, Chief Executive Officer, Director
David W. Osborne
Co-Founder, Chief Technical Officer
John W. Smither
Chief Financial Officer
Patricia A. Turney
Senior Vice President - Manufacturing
Scott L. Burrows
Vice President - Finance
Jay Ramsinghani
Vice President of Commercial Strategy and Operations
Kimberly Lathroum
Vice President of Marketing
Heather Rowe Armstrong
Vice President of Investor Relations and Corporate Communications
Business Overview
Arcutis Biotherapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. Its portfolio is comprised of topical treatments with potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology. Its strategy is to identify and develop treatments against validated biological targets in dermatology that deliver a differentiated clinical profile that addresses major shortcomings of existing therapies in targeted indications. Its products pipelines include ARQ-151, ARQ-154, ARQ-252 and ARQ-255.
Financial Overview
For the nine months ended 30 September 2020, ArcutisBiotherapeutics Inc revenues was not reported. Net lossincreased from $29.4M to $101.6M. Higher net loss reflectsResearch and development - Balancing val increase from$25.6M to $85.7M (expense), General and administrative -Balancing increase from $4.2M to $11.6M (expense),Stock-based Compensation in SGA increase from $223K to$3.1M (expense).
Employees: 29 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $993.66M as of Sep 30, 2020
Annual revenue (TTM): $0.00M as of Sep 30, 2020
EBITDA (TTM): -$115.46M as of Sep 30, 2020
Net annual income (TTM): -$114.20M as of Sep 30, 2020
Free cash flow (TTM): -$97.49M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 43,634,480 as of Oct 31, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.